MNG668
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.504
- TNFA_SIGNALING_VIA_NFKB+0.500
- MYC_TARGETS_V2+0.489
- INFLAMMATORY_RESPONSE+0.427
- MYC_TARGETS_V1+0.423
- ALLOGRAFT_REJECTION+0.415
- MTORC1_SIGNALING+0.410
- HYPOXIA+0.397
- NOTCH_SIGNALING+0.386
- G2M_CHECKPOINT+0.374
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.253
- SPERMATOGENESIS-0.080
- HEDGEHOG_SIGNALING-0.075
- MYOGENESIS-0.009
- KRAS_SIGNALING_DN+0.001
- XENOBIOTIC_METABOLISM+0.021
- ANGIOGENESIS+0.027
- PROTEIN_SECRETION+0.034
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.045
- OXIDATIVE_PHOSPHORYLATION+0.048
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.888 |
| 2 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.882 |
| 3 | DE370889-1057-4355-AFD8-CCFCDC6CD00F | — | — | 0.882 |
| 4 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.878 |
| 5 | R275 | — | — | 0.877 |
| 6 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.875 |
| 7 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.873 |
| 8 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.871 |
| 9 | B614FC9C-BFE0-4C15-BB5E-DAF4FA9D11D5 | — | — | 0.869 |
| 10 | C13F6AB6-41C0-4F51-A240-BA4F4410B68E | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.504 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.489 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.427 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.423 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.415 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| HYPOXIA | 0.397 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.386 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.374 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.351 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.338 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.323 | Idelalisib | — uncovered |
| COMPLEMENT | 0.319 | Inavolisib | — uncovered |
| APOPTOSIS | 0.298 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.293 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.279 | Inavolisib | — uncovered |
| PEROXISOME | 0.277 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.274 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.264 | Inavolisib | — uncovered |